Login to Your Account

EyeGate Reports Positive Data for Ophthalmic Drug/Device

By Catherine Shaffer
Staff Writer

Wednesday, April 10, 2013

In a Phase III trial, an ocular therapeutic product, EGP-437, being developed by EyeGate Pharma Inc., of Waltham, Mass., was noninferior to prednisolone acetate 1 percent ophthalmic suspension for anterior uveitis. EGP-437 comprises a formulation of dexamethasone delivered into the eye using an ocular iontophoresis device.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription